While significant progress has been made with immunotherapy for blood cancers, its effectiveness in treating solid tumors remains limited. A key factor contributing to this low success rate is the ...
SINGAPORE, 17 April 2025 – T Cell Diagnostics Pte. Ltd. (“TCD”) has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results